🏭 Environmental & Occupational Lung Diseases Pneumoconioses · Inhalational Injuries · High‑Altitude Illness for Medical Students

1. Overview: The Importance of Occupational History

Key Principle A detailed occupational and environmental exposure history is essential for diagnosing many chronic lung diseases. Ask about job title, specific tasks, materials handled, duration of exposure, and use of respiratory protection.

• Latency from exposure to disease can be decades (e.g., asbestosis, mesothelioma).
• Concurrent exposures (e.g., smoking + asbestos) can synergistically increase risk.
• Many occupational lung diseases are preventable with proper workplace controls and respiratory protection.

2. Pneumoconioses: Mineral Dust‑Induced Lung Disease

Pneumoconiosis is parenchymal lung disease caused by inhalation and deposition of inorganic mineral dusts, leading to inflammation and fibrosis.

Silicosis

• Exposure: Inhalation of crystalline silica (quartz). Occupations: sandblasting, mining, stone cutting, foundry work, ceramics, hydraulic fracturing.
• Pathology: Silica particles ingested by alveolar macrophages → inflammasome activation (NALP3) → release of IL‑1β, TNF‑α → fibroblast proliferation and collagen deposition. Silicotic nodules (concentric whorled collagen) in upper lobes.
• Clinical forms:
  • Chronic Simple Silicosis: 10‑30 years after low‑moderate exposure. Asymptomatic or mild dyspnea. CXR: small rounded opacities in upper zones.
  • Progressive Massive Fibrosis (PMF): Coalescence of nodules into large masses >1 cm. Severe dyspnea, hypoxemia.
  • Accelerated Silicosis: 5‑10 years after heavy exposure. Rapid progression.
  • Acute Silicosis (Silicoproteinosis): Months to <5 years after massive exposure. Alveolar filling with proteinaceous material (PAP‑like). Rapid respiratory failure.
• Complications: Markedly increased risk of tuberculosis (silicotuberculosis) — silica impairs macrophage function. Also increased risk of lung cancer (IARC Group 1), COPD, autoimmune disease (scleroderma, RA).
• Imaging: CXR: upper lobe predominant nodules, "eggshell calcification" of hilar lymph nodes (pathognomonic). CT: centrilobular and subpleural nodules, PMF masses.
• Diagnosis: Compatible exposure history + radiographic findings + exclusion of other causes. Biopsy rarely needed.
• Management: No specific therapy. Remove from exposure, treat complications (TB screening, vaccinations), supportive care. Lung transplant for end‑stage.

Coal Worker's Pneumoconiosis (CWP)

• Exposure: Coal dust (carbon). Coal mining, processing.
• Pathology: Coal macules (dust‑laden macrophages around respiratory bronchioles) → centrilobular emphysema. PMF can develop.
• Clinical: Often asymptomatic. May progress to PMF with dyspnea, cough, black sputum (melanoptysis).
• Imaging: CXR: small rounded opacities, upper lobe predominance. PMF: large masses.
• Caplan Syndrome: CWP + rheumatoid arthritis → large, rapidly appearing rounded nodules in lung periphery.
• Complications: Increased risk of COPD (chronic bronchitis, emphysema), but no increased risk of lung cancer or TB (unlike silicosis).
• Management: Similar to silicosis; supportive care.

Asbestosis & Asbestos‑Related Diseases

• Exposure: Asbestos fibers (chrysotile, amosite, crocidolite). Occupations: shipbuilding, insulation, construction, brake lining, demolition.
• Pathology: Inhaled fibers reach alveoli → chronic inflammation → interstitial fibrosis (lower lobe predominance). Ferruginous bodies (asbestos fibers coated with iron‑protein) in tissue.
• Spectrum of Asbestos‑Related Disease:
  • Pleural Plaques: Benign, discrete fibrous thickening of parietal pleura. Most common manifestation. Often asymptomatic. Not premalignant.
  • Benign Asbestos Pleural Effusion: Exudative effusion, often bloody, usually <10 years after exposure.
  • Diffuse Pleural Thickening: Extensive visceral pleural fibrosis → restrictive defect.
  • Rounded Atelectasis (Folded Lung): Pleural‑based mass with "comet tail" sign.
  • Asbestosis: Parenchymal fibrosis (lower lobe predominant). Latency 15‑40 years. Clinical: progressive dyspnea, crackles, clubbing. CXR/CT: reticular opacities, subpleural lines, honeycombing (UIP pattern).
  • Lung Cancer: Asbestos is a carcinogen (IARC Group 1). Risk increases synergistically with smoking (multiplicative, not just additive).
  • Mesothelioma: Malignant tumor of pleura (or peritoneum). Latency 20‑50 years. Not related to smoking. Presents with chest pain, pleural effusion, pleural thickening. Poor prognosis (median survival ~12‑18 months).
• Diagnosis: Exposure history + compatible imaging + exclusion of other causes. Biopsy may be needed for mesothelioma or lung cancer.
• Management: No specific therapy for asbestosis. Smoking cessation critical. Mesothelioma: chemotherapy (pemetrexed + cisplatin), immunotherapy, palliative care.

Berylliosis (Chronic Beryllium Disease)

• Exposure: Beryllium metal or salts. Occupations: aerospace, electronics, nuclear weapons, dental alloys.
• Pathophysiology: Type IV hypersensitivity (granulomatous) reaction to beryllium in genetically susceptible individuals (HLA‑DPB1 Glu⁶⁹ variant). Non‑caseating granulomas indistinguishable from sarcoidosis.
• Clinical: Dyspnea, cough, fatigue, weight loss. May have extrapulmonary involvement (skin, lymph nodes).
• Diagnosis: Beryllium Lymphocyte Proliferation Test (BeLPT) — blood or BAL lymphocytes proliferate when exposed to beryllium. Confirm with transbronchial biopsy showing non‑caseating granulomas.
• Management: Remove from exposure. Corticosteroids for symptomatic/progressive disease. Methotrexate or azathioprine as steroid‑sparing agents.

Other Pneumoconioses

Disease	Exposure	Key Features
Siderosis	Iron oxide dust (welding, foundry)	Benign; CXR shows fine nodules, no fibrosis. No symptoms.
Stannosis	Tin oxide	Benign; similar to siderosis.
Baritosis	Barium sulfate	Benign; heavy nodular opacities on CXR.
Hard Metal Lung Disease	Cobalt + tungsten carbide (tool grinding)	Giant cell interstitial pneumonia (GIP). Can progress to fibrosis.
Talcosis	Talc (cosmetics, rubber, ceramics)	Fibrosis similar to asbestosis; talc may contain asbestos.

3. Hypersensitivity Pneumonitis (HP)

• Definition: Immune‑mediated interstitial lung disease caused by inhalation of organic antigens (or certain low‑molecular‑weight chemicals) in sensitized individuals.
• Pathophysiology: Type III (immune complex) and Type IV (T‑cell mediated) hypersensitivity.

Common Syndromes & Exposures

Syndrome	Antigen Source	Antigen
Farmer's Lung	Moldy hay, grain	Thermophilic actinomycetes (Saccharopolyspora rectivirgula)
Bird Fancier's Lung	Bird droppings, feathers	Avian proteins
Humidifier Lung	Contaminated water in humidifiers/AC	Thermophilic actinomycetes, bacteria, fungi
Hot Tub Lung	Contaminated hot tub water	Mycobacterium avium complex (MAC) — non‑infectious, hypersensitivity reaction
Mushroom Worker's Lung	Mushroom compost	Thermophilic actinomycetes
Chemical HP	Isocyanates (paints, foams), anhydrides	Low‑molecular‑weight chemicals acting as haptens

Clinical Presentation

• Acute HP: Flu‑like illness (fever, chills, myalgia, dyspnea, cough) 4‑8 hours after heavy exposure. Resolves within 24‑48h with removal.
• Subacute HP: Insidious dyspnea, cough, fatigue, weight loss over weeks to months.
• Chronic HP: Progressive fibrosis, often indistinguishable from IPF/UIP. May occur without recognized acute episodes.

Diagnosis

• High index of suspicion + detailed exposure history.
• HRCT: Centrilobular ground‑glass nodules, mosaic attenuation (air trapping on expiratory images), upper lobe predominance. Chronic HP: reticulation, traction bronchiectasis, honeycombing.
• BAL: Lymphocytosis (>20‑30%, often >50%), CD4/CD8 ratio variable (often <1 in HP).
• Serum precipitins (IgG antibodies): Suggest exposure, not diagnostic.
• Lung biopsy: Poorly formed non‑caseating granulomas, bronchiolocentric inflammation, giant cells.

Management

• Antigen avoidance is the cornerstone. May require change of occupation or hobby, or extensive environmental remediation.
• Corticosteroids for symptomatic acute/subacute HP. No proven benefit for chronic fibrotic HP.
• Antifibrotics (nintedanib) approved for progressive fibrosing HP despite antigen avoidance.

4. Occupational Asthma & Work‑Related Asthma

• Definition: Asthma caused by workplace exposure to a specific agent. Distinct from work‑exacerbated asthma (pre‑existing asthma worsened by workplace irritants).
• Accounts for ~10‑15% of adult‑onset asthma.

Types of Occupational Asthma

• Immunologic (Allergic) OA: Sensitization to a workplace agent. Latency period (months to years). IgE‑mediated (high‑molecular‑weight proteins) or non‑IgE (low‑molecular‑weight chemicals acting as haptens).
• Irritant‑Induced OA (Reactive Airways Dysfunction Syndrome — RADS): Acute onset after single high‑level exposure to irritant gas, fume, or vapor (e.g., chlorine, ammonia, smoke). No latency.

Common Causative Agents

Category	Examples	Occupations
High‑Molecular‑Weight (Proteins)	Flour, animal dander, latex, enzymes	Bakers, lab workers, healthcare, detergent industry
Low‑Molecular‑Weight (Chemicals)	Isocyanates, anhydrides, wood dust, metals (platinum, nickel, chromium), persulfates	Spray painters, plastics, hairdressers, metal workers

Diagnosis

• Objective diagnosis of asthma (spirometry with bronchodilator response, methacholine challenge).
• Establish work relationship: Serial peak expiratory flow (PEF) monitoring at work and away from work (at least 4 readings/day for 2‑3 weeks).
• Specific inhalation challenge (gold standard, performed in specialized centers).
• Immunologic testing (skin prick or specific IgE) for select agents.

Management

• Early removal from exposure is the most effective intervention. Complete remission possible if removed early.
• Standard asthma pharmacotherapy (ICS, bronchodilators).
• Workplace modifications (substitution, ventilation, respiratory protection) if removal not possible.
• Workers' compensation implications.

5. Inhalational Injuries & Toxic Exposures

Smoke Inhalation

• Thermal injury: Usually limited to upper airway (due to heat dissipation). Supraglottic edema → stridor, airway obstruction. Early intubation if suspected.
• Chemical injury: Inhalation of products of combustion (carbon monoxide, hydrogen cyanide, aldehydes, acrolein) → tracheobronchitis, bronchospasm, pulmonary edema, ARDS.
• Carbon Monoxide (CO) Poisoning: CO binds hemoglobin with 200‑250× affinity of O₂ → tissue hypoxia. Symptoms: headache, confusion, coma. Cherry‑red skin is a late sign. Diagnosis: elevated carboxyhemoglobin (COHb) on co‑oximetry. Standard pulse oximetry is falsely normal. Treatment: 100% O₂ via non‑rebreather; hyperbaric O₂ for severe poisoning (COHb >25%, neurologic symptoms, cardiac ischemia).
• Cyanide Poisoning: Product of combustion of synthetic materials (plastics, upholstery). Binds cytochrome oxidase → anaerobic metabolism, lactic acidosis. High anion gap metabolic acidosis, normal PaO₂. Treatment: Hydroxocobalamin (Cyanokit) — binds cyanide to form cyanocobalamin (vitamin B12).

Other Toxic Inhalants

Agent	Source / Occupation	Clinical Effects
Chlorine Gas	Industrial accidents, mixing bleach + acid	Upper airway irritation, bronchospasm, pulmonary edema. Delayed onset possible.
Ammonia	Refrigeration, fertilizer, cleaning	Severe mucosal injury, laryngeal edema, bronchiectasis (chronic).
Nitrogen Dioxide (NO₂)	Silo Filler's Disease (fermenting silage), welding, combustion	Biphasic: initial mild irritation, then severe pulmonary edema 12‑48h later. Diffuse alveolar damage.
Phosgene	Chemical manufacturing, welding near chlorinated solvents	Delayed pulmonary edema (12‑24h).
Metal Fume Fever	Welding galvanized steel (zinc oxide fumes)	Self‑limited flu‑like illness 4‑12h after exposure. Resolves within 24‑48h.
Polymer Fume Fever	Overheated Teflon (PTFE)	Similar to metal fume fever; may cause severe pneumonitis.

6. High‑Altitude Illness

High‑Altitude Pulmonary Edema (HAPE)

• Non‑cardiogenic pulmonary edema occurring in susceptible individuals ascending rapidly to altitudes >2,500‑3,000 meters (8,000‑10,000 ft).
• Pathophysiology: Hypoxic pulmonary vasoconstriction → uneven, exaggerated vasoconstriction in some areas → overperfusion of non‑constricted vessels → capillary stress failure → high‑permeability edema.
• Risk factors: Rapid ascent, history of HAPE, strenuous exertion, respiratory infection, cold.
• Clinical: Dyspnea at rest, cough (initially dry, then pink frothy sputum), crackles, hypoxemia. Usually occurs 2‑4 days after ascent.
• Prevention: Gradual ascent (<300‑500 m/day above 3,000 m), acetazolamide (prophylaxis not specifically for HAPE but reduces AMS; nifedipine or tadalafil for HAPE‑susceptible individuals).
• Treatment: Descent (at least 500‑1,000 m) is definitive. Supplemental O₂, portable hyperbaric chamber, nifedipine (pulmonary vasodilator), phosphodiesterase‑5 inhibitors (sildenafil, tadalafil).

Other High‑Altitude Syndromes

• Acute Mountain Sickness (AMS): Headache + nausea, fatigue, dizziness. Occurs within 6‑12h of ascent. Treat with rest, descent, acetazolamide, dexamethasone.
• High‑Altitude Cerebral Edema (HACE): Life‑threatening; ataxia, confusion, coma. Immediate descent, dexamethasone, O₂.

7. Diving‑Related Lung Disorders

Pulmonary Barotrauma (Arterial Gas Embolism)

• Overexpansion of lungs during ascent (breath‑holding or air trapping) → alveolar rupture → air enters pulmonary veins → systemic arterial gas embolism (AGE).
• Clinical: Sudden onset of neurologic symptoms (stroke‑like), cardiac arrest, loss of consciousness within minutes of surfacing.
• Treatment: Immediate 100% O₂, hyperbaric oxygen therapy (HBOT).

Decompression Sickness (DCS, "The Bends")

• Inert gas (nitrogen) bubbles form in tissues and blood during ascent from depth.
• Type I (mild): Joint pain, skin marbling (cutis marmorata).
• Type II (severe): Neurologic (spinal cord → paraplegia, paresthesia), pulmonary ("chokes" — dyspnea, chest pain, cough).
• Treatment: 100% O₂, HBOT (recompression).

8. Other Environmental Lung Diseases

Condition	Exposure / Cause	Key Features
Air Pollution‑Related Disease	Particulate matter (PM2.5, PM10), ozone, NO₂, SO₂	Exacerbations of asthma/COPD, increased cardiovascular mortality, lung cancer. Long‑term exposure → reduced lung growth in children, accelerated FEV₁ decline.
Radon‑Induced Lung Cancer	Radon gas (radioactive decay of uranium in soil) accumulating in homes	Second leading cause of lung cancer after smoking. Synergistic with smoking. Testing and mitigation recommended.
Byssinosis	Cotton, flax, hemp dust (textile workers)	"Monday morning chest tightness" — symptoms improve over work week. Due to endotoxin.
Bagassosis	Moldy sugarcane residue	Hypersensitivity pneumonitis.
Popcorn Lung (Bronchiolitis Obliterans)	Diacetyl (artificial butter flavoring) in microwave popcorn factories, e‑cigarette flavorings	Fixed airway obstruction, unresponsive to bronchodilators. Obliterative bronchiolitis on biopsy.

9. Quick Reference: Occupational Lung Disease Pearls

---